A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT07518186
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JNJ-79635322 — DRUG
    JNJ-79635322 will be administered as SC injection.
  • Teclistamab — DRUG
    Teclistamab will be administered as SC injection.

Study Details

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

Key Dates

First listed
Apr 8, 2026
Start date
May 31, 2026
Status verified
Aug 2026
Primary completion
Apr 29, 2029
Completion
Dec 8, 2032

Study Design

Enrollment
700 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: JNJ-79635322
    Participants will receive subcutaneous (SC) dose of JNJ-79635322 treatment of a finite duration or intolerable toxicity (whichever is first).
  • Active Comparator: Arm B: Teclistamab
    Participants will receive teclistamab as a SC injection until PD or intolerable toxicity.

Primary Outcome Measure

Complete Response (CR) or Better [ Time Frame: Up to approximately 41 months ]

Central Contacts

Locations (35)

FacilityCityStateZIPSite coordinators
Alabama OncologyBirminghamAlabama35211-
Mayo Clinic 1PhoenixArizona85054-
Highlands Oncology GroupSpringdaleArkansas72762-
Beverly Hills Cancer Center Clinical Research Advisors LLCBeverly HillsCalifornia90211-
UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory CareIrvineCalifornia92612-
Valkyrie Clinical TrialsLos AngelesCalifornia90067-
University of California Irvine Medical CenterOrangeCalifornia92868-
Colorado Blood Cancer InstituteDenverColorado80218-
University of Connecticut Health CenterFarmingtonConnecticut06030-
Mayo Clinic JacksonvilleJacksonvilleFlorida32224-
Memorial Cancer InstitutePembroke PinesFlorida33026-
Emory UniversityAtlantaGeorgia30322-
Rush University System for HealthChicagoIllinois60607-
Franciscan HealthIndianapolisIndiana46237-8601-
University of Iowa Hospitals and ClinicsIowa CityIowa52242-
Mission Cancer Blood University of Iowa Health CareWaukeeIowa50263-
Norton Cancer InstituteLouisvilleKentucky40207-
LSU Health Feist Weiller Cancer CenterShreveportLouisiana71103-
Karmanos Cancer InstituteDetroitMichigan48201-
University Of Minnesota Medical CenterMinneapolisMinnesota55455-
Mayo ClinicRochesterMinnesota55905-
Nebraska Cancer SpecialistsOmahaNebraska68130-
Astera Cancer CareEast BrunswickNew Jersey08816-
Christus St. Vincent Regional Cancer CenterSanta FeNew Mexico87505-
New York Oncology HematologyAlbanyNew York12208-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long IslandMineolaNew York11501-
NYU Langone Health ManhattanNew YorkNew York10016-
New York Cancer and Blood SpecialistsShirleyNew York11967-
Gabrail Cancer CenterCantonOhio44718-
The Christ HospitalCincinnatiOhio45069-
Dayton Physicians Network UrologyDaytonOhio45415-
Bon Secours Saint Francis Cancer CenterGreenvilleSouth Carolina29607-
Baylor University Medical CenterDallasTexas75246-
Joe Arrington Cancer Research Treatment CenterLubbockTexas79410-
Utah Cancer SpecialistsSalt Lake CityUtah84102-

Find similar trials in Birmingham, AL

Nationwide
Multiple myeloma trialsOncology trialsBlood cancer trials
By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Alabama Oncology· Birmingham, ALMayo Clinic 1· Phoenix, AZHighlands Oncology Group· Springdale, ARBeverly Hills Cancer Center Clinical Research Advisors LLC· Beverly Hills, CAUC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care· Irvine, CAValkyrie Clinical Trials· Los Angeles, CA

Related Studies